- Home
- NMAI vs QTRX Comparison
NMAI vs QTRX Comparison
Compare NMAI & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | QTRX |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.9M | 352.7M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NMAI | QTRX |
|---|---|---|
| Price | $12.89 | $6.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | 74.8K | ★ 804.7K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $130,203,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $28.28 |
| P/E Ratio | $19.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.60 | $4.05 |
| 52 Week High | $12.55 | $12.41 |
Technical Indicators
Market Signals| Indicator | NMAI | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 49.10 |
| Support Level | $12.75 | $6.52 |
| Resistance Level | $13.15 | $7.55 |
| Average True Range (ATR) | 0.16 | 0.42 |
| MACD | -0.03 | -0.16 |
| Stochastic Oscillator | 22.58 | 20.80 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.